July 2026 in “Dermatology and Therapy” Baricitinib and ritlecitinib are both effective and safe for treating severe alopecia areata.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
1 citations
,
January 2022 in “Journal of Biosciences and Medicines” Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
4 citations
,
November 2021 in “Journal of Clinical Medicine” Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
February 2024 in “Research Square (Research Square)” Proteins from Tianshan red deer abomasum have strong anti-inflammatory, anti-tumor, and antioxidant effects.
38 citations
,
February 2009 in “Journal of The European Academy of Dermatology and Venereology” Severe vertex pattern hair loss may indicate a higher risk for artery plaque buildup.
8 citations
,
August 2023 in “Journal of Investigative Dermatology” Corin speeds up wound healing by helping skin cells move and grow.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.
December 2015 in “PLOS ONE”
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
Early recognition and zinc treatment can effectively improve acrodermatitis symptoms.
26 citations
,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
July 2026 in “Journal of the American Academy of Dermatology”
1 citations
,
January 1970 Precise objectives can improve student achievement in health education.
April 2021 in “Journal of Investigative Dermatology” Arg1+ macrophages may play a role in causing alopecia areata.
10 citations
,
November 2020 in “American Journal Of Pathology” Integrin β1 is crucial for liver structure and function, preventing fibrosis.
10 citations
,
November 2015 in “Experimental Dermatology” Skin RAGE levels are linked to inflammation and cell death.
February 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” Retinoic acid reduces cell damage from oxidative stress.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
24 citations
,
January 2023 in “Cancer Research” AMPK activation may reduce melanoma risk in red-haired individuals.
January 2025 in “Dermatologic Therapy” Alopecia areata may be linked to higher heart disease risk.
September 2023 in “Journal of the American Academy of Dermatology” Severe alopecia areata may increase the risk of hidden artery disease.